Sine AI Secures RMB 100 Million Series B Funding Led by GGV Capital and Files for Hong Kong IPO
VCBeat has learned that Synyi AI recently announced the completion of its RMB 100 million Series B financing round. The round was led by GGV Capital, with continued participation from Sequoia Capital China and ZhenFund.
Regarding this round of financing, Zhang Shaodian, Founder and CEO of Senyi Intelligence, stated: “Over the two years since its establishment, the company has achieved a virtuous cycle in product R&D, market application, and commercial implementation. The primary objective of this financing round is to further increase investment in technological R&D, strengthen our customer service system, and enhance the user experience of our products.”
GGV Capital has long been renowned for its investment footprint in the internet and deep-tech sectors, with portfolio companies such as Airbnb, Alibaba, Qunar, and Youku emerging as industry leaders. This partnership with Senyi Intelligence represents GGV Capital’s strategic move to cultivate a leading enterprise in China’s medical artificial intelligence industry.
Image source: Senyi Intelligence
Technology-Driven, Deeply Rooted in Healthcare
Zhang Shaodian earned his bachelor’s degree in Computer Science from Shanghai Jiao Tong University and later obtained a Ph.D. in Biomedical Informatics from Columbia University in the United States. Upon returning to China, this unequivocally tech-driven CEO focused on the healthcare sector. Under his leadership, Senyi Intelligence has regarded technology as its core competitive advantage and primary engine for growth since its inception. Between 2016 and 2017, Senyi Intelligence directly addressed industry pain points with its leading medical natural language processing (NLP) technology, garnering both industry recognition and investor interest. Shortly after its establishment, the company secured nearly RMB 10 million in angel-round funding from top-tier Chinese venture capital firms, including ZhenFund, Huayan Capital, and Shulan Healthcare. As the lead investor in Senyi Intelligence’s Series A round, Mr. Shen Nanpeng, Global Executive Partner at Sequoia Capital, stated, “China’s artificial intelligence industry is experiencing a major boom. In the healthcare sector, however, AI application is more akin to a marathon; only those achieving technological breakthroughs will emerge as true winners. Zhang Shaodian and the Senyi Intelligence team, with their strong technical backgrounds, prioritize enhancing the R&D capabilities of proprietary AI technologies, which is why they continue to attract investment.”
AI-Empowered, Driving Change
As of early 2018, Senyi Intelligence’s products and services had been deployed in dozens of Grade III hospitals across China. As one of the earliest hospitals in China to adopt an intelligent clinical research platform, Dr. Wang Wei, President of Shanghai Children’s Medical Center, stated: “For clinicians, a practical artificial intelligence product must be grounded in the processing and analysis of existing data, with the goal of identifying or solving real-world clinical problems. It should accelerate the transformation of large-scale clinical data into medical insights that guide clinical practice and truly benefit patients. Senyi Intelligence’s innovative solutions have enabled us to build a learning system that integrates intelligence, professionalism, and efficiency, while serving both physicians and the hospital.”
Effective utilization of medical data not only serves clinical practice but also enables the development of regional-level data applications that benefit patients, healthcare providers, and government agencies through medical artificial intelligence. As a core supplier to China Electronics Data (CEC Data), the “national team” for health and medical big data, Senyi Intelligence has established a large-scale, refined platform for data governance, modeling, and intelligent analysis, thereby achieving comprehensive governance and maximized value extraction from medical data. Currently, it has completed the full integration and governance of regional medical data in the Fuzhou area, initially establishing a regional framework for data security, operations, and application.
Amid the booming market for the medical big data industry, Senyi Intelligence and CEC Data have joined forces to continuously explore and develop compliant, professional, and efficient data application models that meet the needs of industrial development. Li Shifeng, Chairman of CEC Data Services Co., Ltd. and Secretary-General of the Health and Medical Big Data Alliance, stated, “The application of medical artificial intelligence technologies helps establish an industry-level system for medical data governance and standardization. In promoting this concept, Senyi Intelligence shares our vision. Driving the development of data-driven ancillary industries requires the participation of companies like Senyi Intelligence, which continually seek new breakthroughs through practice. This is precisely why we have not only established a cooperative relationship with Senyi but also made strategic investments in the company.”
Actively conduct in-depth exploration in areas such as industry standards and specifications.
As a top-tier venture capital firm focused on investments in Silicon Valley and China, with 18 years of deep engagement in the Chinese market, GGV Capital has consistently monitored technology-driven market transformations and applications. “Our investment in Synyi AI represents a significant step in our strategic layout within China’s healthcare artificial intelligence sector,” said Gary Fu, Managing Partner at GGV Capital. “Amidst the diverse landscape of intelligent healthcare, Synyi AI has chosen a path that serves doctors and hospitals, leveraging proprietary technology to establish high entry barriers. The solutions provided by Synyi AI not only significantly enhance the efficiency of clinical research but also constitute a solid step toward precision medicine and AI-driven healthcare in the long run. Although this journey is arduous and prolonged, we have no doubt that its time will come. We are investing not only in a commercially viable project but also in an endeavor that may benefit humanity. The passion and perseverance demonstrated by Shao Dian and his team have given us confidence, and we are committed to walking this path together with Synyi AI.”
Upon completion of this round of financing,Senyi Intelligence will continue to advance R&D in medical natural language processing, healthcare data governance, and machine learning. While further expanding its team and business operations, the company will actively engage in in-depth exploration of industry standards and specifications.。